Indegene Limited Stock Price Today (NSE: INDGN)
Fundamental Score
Indegene Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Indegene Limited share price today is ₹573.20, up +0.30% on NSE/BSE as of 16 September 2026. Indegene Limited (INDGN) is a Mid-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹13.79K (Cr). The 52-week high for INDGN share price is ₹615.50 and the 52-week low is ₹414.00. At a P/E ratio of 34.30x, INDGN is currently trading below its industry average P/E of 39.78x. The company has a Return on Equity (ROE) of 13.94% and a debt-to-equity ratio of 0.00.
Indegene Limited Share Price Chart — NSE/BSE Historical Performance
Indegene Limited share price chart: 3.60% return over the past month. 52-week high ₹615.50, 52-week low ₹414.00.
Indegene Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹570.35 | ₹574.10 | ₹559.00 | ₹573.20 | 2.05L (Cr) | |
| ₹581.80 | ₹584.85 | ₹568.30 | ₹571.50 | 3.18L (Cr) | |
| ₹571.10 | ₹583.25 | ₹570.30 | ₹578.35 | 2.26L (Cr) | |
| ₹586.00 | ₹589.95 | ₹575.15 | ₹577.35 | 2.58L (Cr) | |
| ₹589.20 | ₹591.00 | ₹580.85 | ₹586.35 | 2.39L (Cr) | |
| ₹597.00 | ₹603.60 | ₹579.20 | ₹589.20 | 4.10L (Cr) | |
| ₹602.80 | ₹604.85 | ₹591.85 | ₹599.35 | 3.36L (Cr) | |
| ₹603.15 | ₹611.40 | ₹598.30 | ₹601.50 | 8.05L (Cr) | |
| ₹603.55 | ₹605.00 | ₹597.05 | ₹600.15 | 3.77L (Cr) | |
| ₹602.40 | ₹613.75 | ₹593.60 | ₹600.15 | 6.85L (Cr) |
Indegene Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹610.05 | ₹614.45 | ₹559.00 | ₹573.20 | -6.04% | |
| ₹523.45 | ₹615.50 | ₹512.30 | ₹611.65 | +16.85% | |
| ₹526.55 | ₹538.50 | ₹481.95 | ₹515.15 | -2.17% | |
| ₹525.50 | ₹550.35 | ₹504.60 | ₹525.40 | -0.02% | |
| ₹499.75 | ₹554.00 | ₹499.75 | ₹521.55 | +4.36% | |
| ₹456.40 | ₹508.45 | ₹442.35 | ₹499.75 | +9.50% | |
| ₹480.00 | ₹488.00 | ₹414.00 | ₹434.60 | -9.46% | |
| ₹480.45 | ₹511.75 | ₹460.50 | ₹496.30 | +3.30% | |
| ₹520.25 | ₹526.60 | ₹455.60 | ₹482.40 | -7.28% | |
| ₹532.65 | ₹544.00 | ₹513.85 | ₹520.45 | -2.29% | |
| ₹544.75 | ₹544.75 | ₹502.80 | ₹531.30 | -2.47% | |
| ₹562.70 | ₹587.30 | ₹531.00 | ₹539.40 | -4.14% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Indegene Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Indegene Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INDGN across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (17.29%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (18.92%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (39.73%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (29.44% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (23.02% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (28.20x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 4.48)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹1899.13 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
High Price-to-Book Ratio (5.26x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (-55.05% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Indegene Limited vs Healthcare Research, Analytics & Technology Peers
Peer Comparison - Healthcare Research, Analytics & Technology
Compare Indegene Limited with 8 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Indegene LimitedIndegene Limite...Selected✓ INDGN • 544172 | 57/100 | ₹573.20₹573 | ₹13785.46₹13785.46 | 34.30Average 34.3 Average | 13.94%Average 13.94% Average | 17.29%Good 17.29% Good | 0.00Excellent 0.0 Excellent | 23.02%Excellent 23.02% Excellent | 29.44%Excellent 29.44% Excellent | 0.39% |
Syngene International LimitedSyngene Interna... SYNGENE • 539268 | 35.4/100 | ₹384.20₹384 | ₹15510.15₹15510.15 | 69.85Average 69.9 Average | 0.00%Poor 0.00% Poor | 8.43%Poor 8.43% Poor | 0.00Excellent 0.0 Excellent | -0.98%Poor -0.98% Poor | 11.35%Good 11.35% Good | 0.30% |
Suven Life Sciences LimitedSuven Life Scie... SUVEN • 530239 | 11.4/100 | ₹358.55₹359 | ₹9465.47₹9465.47 | — — | -78.80%Poor -78.80% Poor | -78.35%Poor -78.35% Poor | 0.00Excellent 0.0 Excellent | — — | -12.00%Poor -12.00% Poor | 0.00% |
Vimta Labs LimitedVimta Labs Limi... VIMTALABS • 524394 | 63.6/100 | ₹623.00₹623 | ₹2782.94₹2782.94 | 34.88Average 34.9 Average | 18.55%Good 18.55% Good | 23.39%Excellent 23.39% Excellent | 0.01Excellent 0.0 Excellent | 29.35%Excellent 29.35% Excellent | 14.09%Good 14.09% Good | 0.35% |
TAKE LimitedTAKE Limited... TAKE • 532890 | 31.2/100 | ₹15.99₹16 | ₹236.55₹236.55 | 18.59Average 18.6 Average | 42.11%Excellent 42.11% Excellent | 18.49%Good 18.49% Good | 0.00Excellent 0.0 Excellent | 15.08%Excellent 15.08% Excellent | -41.25%Poor -41.25% Poor | 0.00% |
NOVELIX PHARMACEUTICALS LIMITENOVELIX PHARMAC... NOVELIX • 536565 | 56.9/100 | ₹79.00₹79 | ₹166.57₹166.57 | 45.85Average 45.8 Average | 8.00%Poor 8.00% Poor | 9.96%Poor 9.96% Poor | 0.09Excellent 0.1 Excellent | 22.72%Excellent 22.72% Excellent | 151.69%Excellent 151.69% Excellent | 0.00% |
Bilcare LimitedBilcare Limited... BI • 526853 | 28.9/100 | ₹93.01₹93 | ₹147.94₹147.94 | 26.80Average 26.8 Average | 1.66%Poor 1.66% Poor | 5.56%Poor 5.56% Poor | 3.15Poor 3.1 Poor | 16.32%Excellent 16.32% Excellent | 3.33%Average 3.33% Average | 0.00% |
Adeshwar Meditex LtdAdeshwar Medite... ADESHWAR • 543309 | 24.6/100 | ₹16.30₹16 | ₹23.52₹23.52 | 19.47Average 19.5 Average | 3.38%Poor 3.38% Poor | 6.02%Poor 6.02% Poor | 0.16Excellent 0.2 Excellent | -6.68%Poor -6.68% Poor | -3.19%Poor -3.19% Poor | 0.00% |
Vanta Bioscience LtdVanta Bioscienc... VANTABIO • 540729 | 23.9/100 | ₹19.60₹20 | ₹13.94₹13.94 | 163.55Average 163.6 Average | 0.76%Poor 0.76% Poor | 1.39%Poor 1.39% Poor | 1.80Average 1.8 Average | -24.21%Poor -24.21% Poor | -28.62%Poor -28.62% Poor | 0.00% |
Top Healthcare Research, Analytics & Technology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Syngene International Limited share price15510.15 Cr
- Suven Life Sciences Limited share price9465.47 Cr
- Vimta Labs Limited share price2782.94 Cr
- TAKE Limited share price236.55 Cr
- NOVELIX PHARMACEUTICALS LIMITE share price166.57 Cr
Indegene Limited PE Ratio History
Historical price-to-earnings ratio for INDGN — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹17.02 | ₹520.45 | 30.6x |
| FY 2024 | ₹14.09 | ₹603.70 | 42.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Indegene Limited Quarterly Performance
Latest quarterly metrics for INDGN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
39.73%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-0.17%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
29.44%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
23.02%
Compounded annual net profit growth over 5 years
Indegene Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for INDGN — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Indegene Limited Financial Statements
Annual income statement, balance sheet and cash flow for Indegene Limited (INDGN) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Indegene Limited
About INDGN (Indegene Limited)
Indegene Ltd is a global healthcare solutions provider that is revolutionizing the way life sciences companies operate. Focusing on the intersection of healthcare, technology, and ...commercialization, Indegene empowers biopharmaceutical, emerging biotech, and medical device organizations to achieve their strategic goals. With a deep understanding of the complex healthcare landscape, Indegene offers a comprehensive suite of solutions, spanning from clinical trial optimization to digital marketing and sales force enablement. They are committed to driving innovation and efficiency across the entire product lifecycle, ultimately accelerating the delivery of life-saving therapies to patients in need. At the core of Indegene's capabilities lies a robust foundation in data analytics, artificial intelligence, and digital technologies. They leverage these tools to uncover actionable insights, optimize marketing campaigns, and personalize patient engagement strategies. Indegene helps clients to transform complex medical data into easily digestible information for patients, healthcare professionals, and payers. Through its enterprise commercial and medical solutions, Indegene partners with organizations to navigate the ever-evolving regulatory landscape and optimize their market access strategies. They also provide medical and clinical solutions that include but not limited to literature reviews, publications and more. Indegene is a catalyst for change in the healthcare industry, helping organizations embrace the power of digital transformation to improve patient outcomes. By combining deep industry expertise with cutting-edge technologies, Indegene is uniquely positioned to empower life sciences companies to thrive in the digital age. Through their omnichannel activation services, they support companies to effectively communicate with their target audiences across multiple channels, building trust and brand loyalty. Their dedication to excellence and customer-centric approach makes them a trusted partner for organizations seeking to unlock the full potential of their life-saving products.
Company Details
Key Leadership
INDGN Share Price: Frequently Asked Questions
What is the current share price of Indegene Limited?
Indegene Limited (INDGN) trades at ₹573.20 on NSE and BSE. Market cap ₹13.79K (Cr). Educational data only.
What is the P/E ratio of Indegene Limited?
Indegene Limited has a P/E of 34.30x vs industry average 39.78x.
What is the Bull Run score for Indegene Limited?
Indegene Limited has a Bull Run score of 57/100 based on 25+ financial parameters.
Does Indegene Limited pay dividends?
Indegene Limited has a dividend yield of 0.39%. Past dividends don't guarantee future payments.
What is the ROE of Indegene Limited?
Indegene Limited has ROE of 13.94%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Indegene Limited?
Indegene Limited has debt-to-equity of 0.00.
Is Indegene Limited a good investment?
Bull Run gives Indegene Limited a score of 57/100. This is not investment advice — consult a SEBI-registered advisor.